Such findings demonstrate that TLR4, and presumably TLR2, can be activated through mechanisms other than those utilized by PAMPs and imply that pharmacological interventions specifically aimed at these pathways of cellular interaction may reduce pathologic inflammatory processes that contribute to crucial illness without compromising the beneficial roles of TLR2 and TLR4 in innate immunity against bacterial infection. evidence that TLR4 and TLR2 are not only receptors for bacterial products, but also can be activated through other mechanisms relevant to the pathophysiology of crucial illnesses. There is evidence that TLR4 and TLR2 are involved in ischemia-reperfusion injury and trauma where Gram-negative or Gram-positive bacteria are not detectible in the blood circulation or local organ sites, such as the lungs. In these settings TLRs can transduce other proinflammatory signals and thereby contribute to cellular activation leading to acute lung injury and other organ system dysfunction. The consequences of TLR4 and TLR2 activation through reactive oxygen species (ROS), warmth shock proteins, and other non-LPS dependent mechanisms may be different from those associated with binding of the membrane component of bacteria to TLR4 or TLR2 and may produce different signatures of gene Triclabendazole activation and release of proinflammatory mediators. Keywords:TLR4, TLR2, Sterile inflammation, Ischemia-reperfusion, Trauma, Crucial care medicine == Introduction == Toll-like receptors (TLRs) were initially characterized by their interactions with bacterial ligands and involvement in cellular activation associated with contamination and sepsis. Toll-like receptors 2 (TLR2) and 4 (TLR4) were originally described as realizing pathogen-associated molecular patterns (PAMPs) derived from bacteria and other microorganisms. However, recent studies have shown that both TLR2 and TLR4 can identify nonmicrobial ligands, including danger-associated molecular patterns (DAMPs) and other products of inflamed tissue. Engagement of TLR2 and TLR4 initiates signaling through intracellular pathways that lead to activation of transcription factors, such as nuclear factor-B (NF-B) and the interferon regulatory factor 3 (IRF3), that result in transcription of genes, including proinflammatory cytokines and other immunoregulatory molecules. Recent studies in animals have shown that activation of TLR2 and TLR4 by conversation with non-microbial mediators can play an important role in contributing to organ dysfunction in settings associated with crucial illness, such as hemorrhage and ischemia/reperfusion injury, in which LPS or other bacterial products are not present. In addition to recent studies that have provided greater detail concerning the signaling pathways activated by TLR2 and TLR4, there is increasing understanding of the nature of the molecular interactions occurring between TLR2 and TLR4 with accessory molecules as well as with their ligands and antagonists. New approaches to inhibit TLR2 and TLR4, including antibodies and small molecules, provide therapeutic methods that may have clinical power in crucial care medicine. In this article, we review the potential roles of TLR2 and TLR4 in contributing to non-septic acute organ dysfunction and also speculate around the potential power of inhibiting TLR2- and TLR4-associated cellular activation in improving outcome from crucial illnesses in which microbial products do not appear to play a pathogenic role. In order to review the possible role of TLR2 and TLR4 in pathophysiologic processes relevant to crucial care medicine, we searched the PubMed database by successively entering the terms Toll-like receptor, TLR, TLR2, or TLR4 with the following terms: sterile inflammation, ischemia-reperfusion, Triclabendazole trauma, hemorrhage, multiorgan failure, heat shock protein, HMGB1, reactive oxygen species, hyaluronic acid and crucial care. == TLR 2 and 4 signaling pathways == Engagement of ligands with the TLR2/TLR1 or TLR2/ TLR6 heterodimer or the TLR4 homodimer induces activation of intracellular signaling pathways through recruitment of the Toll-like/interleukin 1 receptor (TIR) adapters MyD88 and Mal, resulting in activation of the IB kinase (IKK) complex with subsequent degradation of IB, the inhibitor of NF-B, KIAA1732 in the 26S proteasome [13]. Decreased cytoplasmic concentrations of IB permit NF-B to translocate from your cytosol to the nucleus and activate B-dependent genes, which include proinflammatory cytokines and other mediators of inflammatory and immune responses [1,4]. Engagement of TLR2 or TLR4 by their ligands results in cellular activation through a common pathway that involves the TIR Triclabendazole adapters myeloid differentiation main response gene (88) (MyD88) and MyD88 adapter-like (Mal) [1]. In addition, TLR4-induced signaling can occur through an alternate pathway that.